U.S. Vasopressin Market Analysis & Forecast: 2026-2033

U.S. Vasopressin Market Analysis & Forecast: 2026-2033

The U.S. vasopressin market is estimated to be valued at USD 1,787.3 Mn in 2026 and expected to reach USD 4,657.5 Mn by 2033, witnessing a CAGR of 14.7% over the forecast period (2026-2033).

Key Takeaways

• Based on Type, the intravenous injection segment is expected to hold 65% share of the market in 2026.
• Based on Application, the vasodilatory shock segment is expected to lead the market with 55% share in 2026.
• Based on End User, the hospitals segment is projected to capture 70% share of the market in 2026.

Market Overview

Vasopressin is antidiuretic hormone. It is naturally secreted by the pituitary gland, which acts on the kidneys and blood vessels. Vasopressin can be used to treat diabetes insipidus through different routes of administration such as intravenous injection, intramuscular injection, and others.

Vasopressin is widely available in the U.S. and is expected to fuel the growth of U.S. vasopressin market over the forecast period. Some examples of vasopressin injections available in the U.S. for treatment of diabetes include vasopressin injection (Eagle Pharmaceuticals, Inc.), pitressin injection (JHP Pharmaceuticals, LLC), and others.

Current Events and their Impacts on the U.S. Vasopressin Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Pricing & Reimbursement

• Average hospital acquisition cost: $45–$65 per vial (20 units/mL).
• Annual hospital expenditure on vasopressin exceeds USD 400 million in the U.S. alone.
• Medicare and private insurers cover vasopressin when used in critical care protocols, reducing patient out-of-pocket costs to near zero.

Segmental Insights

To learn more about this report, Download Free Sample

U.S. Vasopressin Market Insights, By Type - Intravenous injection leads due to rapid delivery and essential use in ICU emergencies

In terms of type, the intravenous injection segment is expected to hold 65% share of the market in 2026, because it is mostly given in critical care settings. Rapid IV delivery is a key part of ICU protocols for septic shock, cardiac arrest, and gastrointestinal bleeding. It has the biggest market share of all the administration routes as it is accurate, works right away, and is used by many hospitals.

U.S. Vasopressin Market Insights, By Application - Vasodilatory shock dominates as vasopressin is crucial for stabilizing septic shock patients

In terms of application, the vasodilatory shock segment is expected to lead the market with 55% share in 2026. According to U.S. critical care guidelines, vasopressin is a second-line vasopressor. The increasing number of sepsis cases, the higher number of ICU admissions, and the fact that it has proven efficacy in stabilizing blood pressure make this the main reason for the high demand for vasopressin across the country.

U.S. Vasopressin Market Insights, By End user - Hospitals hold the largest share, driven by high ICU admissions and advanced treatment infrastructure

In terms of end user, the hospitals segment is projected to capture 70% share of the market in 2026. Emergency rooms and intensive care units give vasopressin every day to people with life‑threatening conditions. Hospitals are still the best place to get vasopressin because they have a large patient volumes, good infrastructure, and support for getting paid. This is much better than clinics or healthcare professionals.

Market Report Scope

U.S. Vasopressin Market Driver

Increasing Regulatory Approvals of Vasopressin

The fact a growing number of regulatory bodies in the U.S. are approving vasopressin is a big reason for the market to expand. These approvals enhance physicians’ confidence, make the drug available for more uses, and make it easier for more patients to get. Hospitals and clinics are using vasopressin increasingly as it becomes more widely accepted for serious conditions like septic shock and cardiac arrest. This trend directly helps the U.S. Vasopressin Market growth because regulatory support makes it easier for new companies to enter the market and speeds up commercialization in a variety of healthcare settings.

High Prevalence of Chronic Diseases and Health Conditions

The increasing prevalence of chronic diseases, including diabetes insipidus, cardiovascular disorders, and septic shock, substantially drives the demand for vasopressin therapies. As people get older and face health problems related to their lifestyles, the need for effective treatments keeps growing. Vasopressin is very important in critical care because it helps keep blood pressure stable and fluid levels in check. Following this, the U.S. Vasopressin market demand is rising quickly due to the urgent need for reliable treatments for complex and life-threatening conditions.

U.S. Vasopressin Market Opportunity

Expanding Therapeutic Applications

Vasopressin's growing uses in medicine are a big chance for healthcare in the U.S. It is becoming more common to use it for conditions like gastrointestinal bleeding, vasodilatory shock, ventricular tachycardia, and fibrillation, in addition to its well-known use in diabetes insipidus. This diversification makes it more useful in emergency medicine and critical care, which will help it be used more widely in hospitals. These approvals directly affect the U.S. Vasopressin Market forecast by opening up new ways for pharmaceutical companies to generate revenue. This shows that the market is likely to keep growing in the coming years.

Analyst Opinion (Expert Opinion)

• In 2025, the U.S. approved vasopressin for more uses, including vasodilatory shock and ventricular fibrillation. This shows a trend in regulation toward more therapeutic uses. Data from hospitals show that vasopressin is used to treat shock in more than 60% of intensive care units, underscoring its critical role in emergency medicine. These approvals should make it easier for multiple departments to use it, which will help it stay at the top of the list of treatments.
• Clinical utilization statistics show that vasopressin is given to about 30–40% of septic shock patients who have refractory hypotension. Studies also demonstrate that vasopressin lowers the need for norepinephrine by almost 25%, which improves patient outcomes and lowers the cost of treatment. This measurable effect on the efficiency of critical care is making hospitals more dependent on vasopressin, making it a key drug on hospital formularies and keeping demand high in the U.S. healthcare system.

Recent Developments

• In February 2026, Eton Pharmaceuticals stated that the FDA had approved DESMODA, an oral solution of desmopressin acetate, for treating central diabetes insipidus. Desmopressin is a synthetic analog of vasopressin, the body’s antidiuretic hormone. This approval gives patients a new oral option that is directly related to vasopressin's role in regulating water balance.
• In October 2025, Tonix Pharmaceuticals declared that the first patient in its FOCUS study was given a dose at Massachusetts General Hospital. The trial is for arginine-vasopressin deficiency (AVP-D), which used to be called central diabetes insipidus. Even though intranasal oxytocin is being tested, the condition is directly linked to vasopressin biology. This means that this research is important for vasopressin-related disorders and patient care.

Market Segmentation

• By Type
  • Intravenous Injection
  • Intramuscular Injection
  • Subcutaneous Injection
  • Others
• By Application
  • Anti-diuretic Hormone Deficiency
  • Gastrointestinal Bleeding
  • Vasodilatory Shock
  • Ventricular Tachycardia
  • Fibrillation
• By End User
  • Hospitals
  • Dental Clinics
  • Others 
• U.S. Vasopressin Market – Competitive Landscape
  • Par Pharmaceutical
  • Pfizer Inc.
  • Eagle Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Cumberland Pharmaceuticals Inc.
  • Reddy’s Laboratories Ltd.
  • Athenex, Inc.
  • Otsuka Holdings Co., Ltd
  • Azevan Pharmaceuticals, Inc.

Sources

Primary Research Interviews

• Vasopressin Drug Manufacturers
• Sterile Injectable Manufacturers & CMOs/CDMOs
• Hospital Pharmacy Procurement Managers
• Critical Care Specialists / Intensivists
• Endocrinologists
• Group Purchasing Organizations (GPOs) / Specialty Distributors
• Others

Databases

• IQVIA
• Clarivate Cortellis
• Evaluate Pharma
• Bloomberg Terminal
• Others

Magazines

• Pharmaceutical Commerce
• Fierce Pharma
• Pharmacy Times
• Drug Topics
• Endocrine News
• Others

Journals

• Journal of Clinical Endocrinology & Metabolism
• Critical Care Medicine
• Annals of Pharmacotherapy
• The New England Journal of Medicine
• Chest
• Others

Newspapers

• Financial Times
• The Wall Street Journal
• Reuters
• Bloomberg News
• BioPharma Dive
• Others

Associations

• Endocrine Society
• Society of Critical Care Medicine (SCCM)
• American Society of Health-System Pharmacists (ASHP)
• American Association of Clinical Endocrinology (AACE)
• American Pharmacists Association (APhA)
• Others

Public Domain Sources

• U.S. Food and Drug Administration (FDA) – Drugs@FDA / Drug Shortages Database
• National Institutes of Health (NIH)
• DailyMed
• Centers for Medicare & Medicaid Services (CMS)
• Agency for Healthcare Research and Quality (AHRQ)
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 8 Years